Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin

Thrombosis and Haemostasis

Volumn 85, Issue 2, 2001, Pages 309-313

  Schneider, D J ^a   Baumann, P Q ^a   Holmes, M B ^a   Taatjes, D J ^a   Sobel, B E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Aspirin; Glycoproteins; Platelet aggregation inhibitors; Platelets

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN; NAPROXEN; SALSALATE;

ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACETYLATION; DRUG DETERMINATION; DRUG INHIBITION; DRUG POTENTIATION; FIBRINOGEN METABOLISM; HEART DISEASE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

EID: 0035122593     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615685     Document Type: Article

References (25)

1. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
2. Aspirin heparin, or both to treat acute unstable angina
3. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
4. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina
5. The mechanism of the effect of aspirin on human platelets: I: Acetylation of a particulate fraction protein
6. Differences between activation thresholds of platelet P-selectin and glycoprotein IIb-IIIa expression and their clinical implications
7. The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine
8. Aspirin does not inhibit adenosine diphosphate-induced platelet-granule release
9. Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of α-granules or lysosomes from human platelets
10. An overview of the results of the EPIC trial
11. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous revascularization
12. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
13. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
14. Blood clotting in minimally altered whole blood
15. Differential effects of anticoagulants on the activation of platelets ex vivo
16. Optimally functional fluorescein isothiocyanate-labeled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation
17. Dose and duration dependence of aspirin-induced augmentation of inhibition of fibrinogen binding by ReoPro
18. Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A
19. Paradoxical inhibition of fibrinogen binding and potentiation of -granule release by specific types of inhibitors of glycoprotein IIb-IIIa
20. Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia
21. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin
22. A new murine monoclonal antibody reports activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex
23. Results from late-breaking clinical trials session at ACCIS '99 and ACC '99. American College of Cardiology
24. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb-IIIa inhibitors
25. Monoclonal antibodies to ligand-occupied conformers of glycoprotein IIb/IIIa alter receptor affinity, specificity, and function